Etoposide plus cisplatin remains best for limited-stage SCLC

Etoposide plus cisplatin, given alongside accelerated hyperfractionated thoracic radiotherapy, remains the gold standard regimen for patients with limited-stage small-cell lung cancer, Japanese researchers say.

Source: MedWire News - Respiratory - January 23, 2014 Category: Respiratory Medicine Source Type: news